Hepatitis Monthly

Published by: Kowsar

Effects of the Chemokine Receptor 5 (CCR5)-Delta32 Mutation on Hepatitis C Virus-Specific Immune Responses and Liver Tissue Pathology in HCV Infected Patients

Abdulkerim Yilmaz 1 , * , Hakan Alagozlu 1 , Ozturk Ozdemir 2 , 3 and Sema Arici 4
Authors Information
1 Department of Gastroenterology, Cumhuriyet University, Sivas, Turkey
2 Department of Medical Genetics, Cumhuriyet University, Sivas, Turkey
3 Department of Medical Genetics, Canakkale Onsekiz Mart University, Canakkale, Turkey
4 Department of Pathology, Cumhuriyet University, Sivas, Turkey
Article information
  • Hepatitis Monthly: July 01, 2014, 14 (7); e11283
  • Published Online: July 1, 2014
  • Article Type: Research Article
  • Received: March 23, 2013
  • Revised: September 28, 2013
  • Accepted: March 7, 2014
  • DOI: 10.5812/hepatmon.11283

To Cite: Yilmaz A, Alagozlu H, Ozdemir O, Arici S. Effects of the Chemokine Receptor 5 (CCR5)-Delta32 Mutation on Hepatitis C Virus-Specific Immune Responses and Liver Tissue Pathology in HCV Infected Patients, Hepat Mon. 2014 ; 14(7):e11283. doi: 10.5812/hepatmon.11283.

Abstract
Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Backgraund
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Footnote
References
  • 1. Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat. 2007; 14(10): 675-87[DOI][PubMed]
  • 2. Baggiolini M, Loetscher P. Chemokines in inflammation and immunity. Immunol Today. 2000; 21(9): 418-20[PubMed]
  • 3. Apolinario A, Majano PL, Alvarez-Perez E, Saez A, Lozano C, Vargas J, et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol. 2002; 97(11): 2861-70[DOI][PubMed]
  • 4. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol. 1999; 163(11): 6236-43[PubMed]
  • 5. Wenzel UO, Stahl RA. Chemokines, renal disease, and HIV infection. Nephron. 1999; 81(1): 5-16[PubMed]
  • 6. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996; 382(6594): 833-5[DOI][PubMed]
  • 7. Venkatesan S, Petrovic A, Van Ryk DI, Locati M, Weissman D, Murphy PM. Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration. J Biol Chem. 2002; 277(3): 2287-301[DOI][PubMed]
  • 8. Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology. 2003; 124(2): 352-60[DOI][PubMed]
  • 9. Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, et al. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology. 2002; 122(7): 1721-8[PubMed]
  • 10. Wald O, Pappo O, Ari ZB, Azzaria E, Wiess ID, Gafnovitch I, et al. The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection. Eur J Immunogenet. 2004; 31(6): 249-52[DOI][PubMed]
  • 11. Mascheretti S, Hinrichsen H, Ross S, Buggisch P, Hampe J, Foelsch UR, et al. Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exp Immunol. 2004; 136(2): 328-33[DOI][PubMed]
  • 12. Goulding C, McManus R, Murphy A, MacDonald G, Barrett S, Crowe J, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut. 2005; 54(8): 1157-61[DOI][PubMed]
  • 13. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol. 2003; 74(3): 360-9[PubMed]
  • 14. Zhdanov KV, Gusev DA, Chirskii VS, Sysoev KA, Iakubovskaia LA, Shakhmanov DM, et al. [Chronic HCV-infection and expression of mRNA of CC-chemokines and their receptors]. Zh Mikrobiol Epidemiol Immunobiol. 2008; (4): 73-8[PubMed]
  • 15. Kusano F, Tanaka Y, Marumo F, Sato C. Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C. Lab Invest. 2000; 80(3): 415-22[PubMed]
  • 16. Larrubia JR, Calvino M, Benito S, Sanz-de-Villalobos E, Perna C, Perez-Hornedo J, et al. The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. J Hepatol. 2007; 47(5): 632-41[DOI][PubMed]
  • 17. Larrubia JR, Benito-Martinez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol. 2008; 14(47): 7149-59[PubMed]
  • 18. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 2008; 48(5): 1440-50[DOI][PubMed]
  • 19. Ksiaa Cheikh Rouhou L, Gorgi YL, Skhiri HA, Aouadi H, Ayed SJ, Sfar I, et al. Chemokine and chemokine receptor gene polymorphism in Tunisian hemodialysis patients with HCV infection. Arab J Nephrol Transplant. 2011; 4(3): 117-24[PubMed]
  • 20. Coenen M, Nattermann J. The role of CCR5 in HCV infection. Eur J Med Res. 2010; 15(3): 97-101[PubMed]
  • 21. Nattermann J, Timm J, Nischalke HD, Olbrich A, Michalk M, Tillmann HL, et al. The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Delta32 mutation. J Hepatol. 2011; 55(6): 1201-6[DOI][PubMed]
  • 22. Ahlenstiel G, Woitas RP, Iwan A, Nattermann J, Feldmann G, Rockstroh JK, et al. Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia. Immunol Invest. 2009; 38(3-4): 284-96[PubMed]
  • 23. Zeremski M, Hooker G, Shu MA, Winkelstein E, Brown Q, Des Jarlais DC, et al. Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol. 2011; 55(3): 545-53[DOI][PubMed]
  • 24. Rauch A, Gaudieri S, Thio C, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics. 2009; 10(11): 1819-37[DOI][PubMed]
  • 25. Fatkenheuer G, Hoffmann C, Slim J, Rouzier R, Keung A, Li J, et al. Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable. J Acquir Immune Defic Syndr. 2010; 53(1): 78-85[DOI][PubMed]
  • 26. Lazzarin A, Than S, Valluri SR, Heera J, Mukwaya G. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program. HIV Clin Trials. 2012; 13(2): 83-9[DOI][PubMed]
  • 27. Sezgin I, Koksal B, Bagci G, Kurtulgan HK, Ozdemir O. CCR2 polymorphism in chronic renal failure patients requiring long-term hemodialysis. Intern Med. 2011; 50(21): 2457-61[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments